Example: Heart Attack

Search clinical trials for: Angiotensin II Type 1 Receptor Blockers

Total 1260 results

NCT00774904

Completed

Adiponectin and Insulin Resistance in Diabetic Nephropathy

Conditions: Diabetic Nephropathy
NCT02788656

Terminated

Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)

Conditions: Congestive Heart Failure
NCT04510623

Recruiting

Host Response Mediators in Coronavirus (COVID-19) Infection

Conditions: COVID-19; SARS-CoV2
NCT00001629

Completed

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

Conditions: Atherosclerosis; Heart Failure, Congestive; Hypertension; Myocardial Infarction
NCT00001628

Completed

The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function

Conditions: Atherosclerosis; Heart Failure, Congestive; Hypertension; Myocardial Infarction
NCT01670903

Unknown status

The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients

Conditions: Aneurysm; Hypertension
NCT00763893

Terminated

Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome

Conditions: Marfan Syndrome
NCT00890591

Completed

Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension

Conditions: Essential Hypertension
NCT00144144

Unknown status

A Study on Ca Blocker Versus AII Antagonists in Hypertension With Type 2 Diabetes

Conditions: Hypertension; Diabetes Mellitus, Type 2
NCT03415906

Withdrawn

Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure

Conditions: Heart Failure
NCT00162955

Completed

Prevention of CHOP-induced Chronic Cardiotoxicity

Conditions: Non-Hodgkin's Lymphoma
NCT00572312

Completed

Optimalization of Nephroprotection Using Atorvastatin (Sortis)

Conditions: Chronic Kidney Disease; Proteinuria
NCT00126516

Completed

Angiotensin II Receptor Blockers (ARB) and ACE Inhibitors (ACEI) on Silent Brain Infarction and Cognitive Decline

Conditions: Brain Infarction; Hypertension
NCT00376272

Completed

GISSI-AF - Use of Valsartan an Angiotensin II AT1-Receptor Blocker in the Prevention of Atrial Fibrillation Recurrence

Conditions: Atrial Fibrillation
NCT01015937

Completed

Effect of Turmeric on Diabetic Nephropathy

Conditions: Diabetic Nephropathy; Proteinuria
NCT00184587

Completed

Prophylactic Treatment of Episodic Cluster Headache

Conditions: Cluster Headache
NCT01609959

Completed

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

Conditions: Hypertension
NCT02248896

Completed

Antihypertensive Medications and the Risk of Sepsis

Conditions: Hypertension
NCT01444833

Unknown status

Changes After Angiotensin Converting Enzyme (ACE) Inhibitor Replacement by Angiotensin II Receptor Type I (AT1) Blocker

Conditions: Hypertension
NCT03315832

Not yet recruiting

Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study

Conditions: Aortic Valve Stenosis; Valsartan; Angiotensin Receptor Antagonists; Transcatheter Aortic Valve Replacement; Heart Valve Prosthesis Implantation; Hypertrophy, Left Ventricular
NCT00791830

Completed

Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan

Conditions: Kidney Failure, Chronic
NCT02360956

Unknown status

Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)

Conditions: Coronary Atherosclerosis
NCT04394117

Recruiting

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease

Conditions: SARS-Cov-2; COVID-19
NCT00417222

Completed

Supplemental Benefit of Angiotensin Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan

Conditions: Chronic Heart Failure
NCT00561704

Completed

Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

Conditions: Obese; Type 2 Diabetes; Diabetic Nephropathy; Glucose Metabolism; Angiotensin II Type 1 Receptor Blockers